Modulation of the systemic inflammatory response by recombinant human interleukin-11 : a prospective randomized placebo controlled clinical study in patients with hematological malignancy
The immunomodulatory activities of recombinant human interleukin-11 (rhIL-11) were investigated in a clinical trial among patients with hematological malignancy, randomized to either rhIL-11 or placebo throughout chemotherapy. Daily serum concentrations of sTNFRI, IL-6, IL-8, TNFalpha, and CRP were...
| Publié dans: | Clinical immunology (Orlando, Fla.). - 1999. - 120(2006), 2 vom: 15. Aug., Seite 129-37 |
|---|---|
| Auteur principal: | |
| Autres auteurs: | , , , , , |
| Format: | Article |
| Langue: | English |
| Publié: |
2006
|
| Accès à la collection: | Clinical immunology (Orlando, Fla.) |
| Sujets: | Clinical Trial Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't Anti-Inflammatory Agents Biomarkers IL11 protein, human Interleukin-11 Interleukin-6 Interleukin-8 plus... |